Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 1 of 15

 
 

Dr. Reddy's Laboratories (NYSE:RDY)

Consensus Rating
Hold
Rating Score
2.0
Ratings Breakdown
1 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$81.00 (17.9% Upside)

About Dr. Reddy's Laboratories

Dr. ReddyDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
5/8/2024BarclaysBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $81.00
1/29/2024BarclaysBoost Price TargetOverweight ➝ Overweight$75.00 ➝ $80.00
1/11/2024Jefferies Financial GroupDowngradeBuy ➝ Underperform
8/29/2023HSBCDowngradeBuy ➝ Hold
6/1/2023BarclaysBoost Price Target$67.00 ➝ $70.00
5/18/2023Sanford C. BernsteinDowngradeOutperform ➝ Market Perform
3/17/2023Bank of AmericaUpgradeNeutral ➝ Buy
1/30/2023JPMorgan Chase & Co.Initiated CoverageUnderweight
11/14/2022Credit Suisse GroupDowngradeNeutral ➝ Underperform
10/31/2022BarclaysBoost Price TargetOverweight$66.00 ➝ $67.00
 

The Only Energy Play You Should Be Looking At (Ad)

Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.

Click here to get all the information about it.